Abstract
Introduction Subjective cognitive decline (SCD) is proposed to indicate transitional stage-2 in the AD continuum, yet longitudinal fluid biomarker data for this stage is scarce. We investigated if blood-based biomarkers in amyloid-positive individuals with SCD (A+SCD) support stage-2 as distinct from AD stages-1 and -3 and identify those at high risk for progression.
Methods We analyzed plasma phospho-tau-181 (p181) and neurofilament-light-chain (NfL) in a prospective multicenter study of 460 participants across the AD continuum, assessing their association with cognition, hippocampal atrophy, and clinical progression.
Results Baseline plasma p181 was elevated and increased faster in A+SCD compared to amyloid-positive cognitively unimpaired (A+CU) individuals (stage-1). NfL rose across A+CU, A+SCD, and A+MCI (stage-3). In A+SCD, higher p181 predicted cognitive decline and transition to MCI.
Discussion Plasma p181 provides biomarker evidence for A+SCD as a distinct pre-dementia AD stage and helps identify individuals at risk for cognitive decline early in the AD continuum.
Systematic Review Research on subjective cognitive decline (SCD) and its association with Alzheimer’s disease (AD), as well as investigations into stage-2 of the AD continuum, is quickly expanding, but fluid biomarker evidence is scarce. We conducted a comprehensive review across PubMed, recent meeting abstracts, and oral presentations, focusing on cross-sectional and longitudinal case-control studies, cohort studies, and meta-analyses.
Interpretation Our plasma phospho-181 tau (p181) findings provide molecular fluid biomarker evidence for A+SCD as a pre-dementia AD stage (stage-2) distinct from A+CU (stage-1). Plasma p181 assessment aids in identifying individuals at risk of future disease progression early in the AD continuum.
Future directions The here proposed concept of SCD as an indicator of stage 2 of the Alzheimer’s disease continuum - supported and stratified by easily accessible blood-based biomarkers - warrants further validation in memory clinics. It could facilitate earlier- and thus even higher-effect - treatments in the pre-dementia stages of AD.
Highlights
A+SCD exhibits a distinct trajectory of plasma p181 compared to A+CU
Higher plasma p181 levels in A+SCD predict PACC5 decline and transition to MCI
Plasma p181 serves as a biomarker that delineates the A+SCD stage from A+CU
HighlightsPlasma p181 levels stratify SCD patients, facilitating early interventions
Competing Interest Statement
David Berron is a scientific co-founder of neotiv GmbH and owns company shares. Frank Jessen reports grant support from Roche and speaker and advisor honorarium from Abbvie, AC immune, Biogen, Eisai, Grifols, Janssen, Lilly, Novo Nordisk, Roche. Matthis Synofzik has received consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Servier, Reata, GenOrph, AviadoBio, Biohaven, Solaxa, Biogen, Zevra, and Lilly, all unrelated to the present manuscript. All other authors report no disclosures.
Funding Statement
The DELCODE study is funded by the German Center for Neurodegenerative Diseases (Deutsches Zentrum fuer Neurodegenerative Erkrankungen, DZNE), reference number BN012. This work was additionally supported by the Clinician Scientist program "PRECISE.net" funded by the Else Kroener-Fresenius-Stiftung (to DM, and MS), by the EU Joint Programme - Neurodegenerative Disease Research GENFI-PROX grant (2019-02248; to MS). DM is supported by the Clinician Scientist program of the Medical Faculty Tuebingen (459-0-0) and the Elite Program for Postdoctoral researchers of the Baden-Wuerttemberg-Foundation (1.16101.21).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee at the Medical Faculty of the Eberhard Karls University and at the University Hospital of Tuebingen (665/2021BO2) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
